In drug development, pharmaceutical companies and academic hospitals develop large databases with information on what a medicine does with the human body, and what the human body does with the medicine. Based on this information "pharmacokinetic" and "pharmacodynamic" (PK/PD) models are created that can help, for example, to design clinical studies for developing new medicines and for defining for example the right dosage for medicines.

By coupling databases from various partners, better statistics can be obtained. This results in improved clinical protocols for the elderly and for children (for which, by nature, less data points are available) and finding optimal dosage forms. A concrete result from the models developed within this TI Pharma consortium is a new dosage regime for the use of morphine in children.

Consortium Partners

The partners of this platform share their data, enabling them to generate powerful mathematical models to predict among others a safe morphine dosing regimen for newborns.

Erasmus University Medical Center
Johnson & Johnson
Universiteit Leiden
University Medical Centre Utrecht
University of Groningen

For more information, please contact 
or call +31 71 332 2030

    “TI Pharma's program managers are experts in the content, enabling them to keep parties focused on the goals that were agreed upon at the outset.”

    Jan Raaijmakers
    Past VP External Scientific Collaborations GSK Europe
    Chair TI Pharma Board of Directors

    Share this page: